BD Q3 revenue $4.88B up 5.1%, adjusted EPS $2.96 up 11.3%, raises FY revenue guidance

BECTON DICKINSON & CO

2023-Q3 EPS reported $4.60 revenue$14,285,000,000

Revenue of $4.88B, up 5.1% as reported, 6.3% currency-neutral; base revenue growth 6.7% as reported.
GAAP diluted EPS $1.36; adjusted diluted EPS $2.96 vs $2.66 YoY, up 11.3%.
Raised full-year base organic revenue growth guidance; maintained full-year adjusted EPS guidance.
Received FDA 510(k) clearance for updated BD Alaris Infusion System, a key BD 2025 milestone.
Completed sale of Surgical Instrumentation platform to STERIS for $540M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BECTON DICKINSON & CO reported financial results for third quarter of fiscal 2023, which ended June 30, 2023.

Period: third quarter of fiscal 2023, which ended June 30, 2023
Result: reported results

Exact text from the filing

On August 3, 2023, Becton, Dickinson and Company (“BD”) issued a press release announcing its financial results for its third fiscal quarter ending June 30, 2023.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

BECTON DICKINSON & CO filing history →

Source: SEC EDGAR

accession 0000010795-23-000072

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.